Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $67000.0.

  • UroGen Pharma's Other Working Capital Changes fell 9636.86% to $67000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 272.04%. This contributed to the annual value of -$1.4 million for FY2024, which is 7512.2% down from last year.
  • UroGen Pharma's Other Working Capital Changes amounted to $67000.0 in Q3 2025, which was down 9636.86% from -$928000.0 recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Other Working Capital Changes ranged from a high of $4.1 million in Q1 2025 and a low of -$5.8 million during Q4 2023
  • Moreover, its 5-year median value for Other Working Capital Changes was $805000.0 (2021), whereas its average is $460947.4.
  • Within the past 5 years, the most significant YoY rise in UroGen Pharma's Other Working Capital Changes was 217054.79% (2023), while the steepest drop was 120287.36% (2023).
  • UroGen Pharma's Other Working Capital Changes (Quarter) stood at $1.4 million in 2021, then crashed by 61.67% to $522000.0 in 2022, then crashed by 1202.87% to -$5.8 million in 2023, then grew by 9.54% to -$5.2 million in 2024, then surged by 101.29% to $67000.0 in 2025.
  • Its last three reported values are $67000.0 in Q3 2025, -$928000.0 for Q2 2025, and $4.1 million during Q1 2025.